Interleukin-6, Interleukin-8, and Interleukin-1 beta cytokine expression (IL-6, IL-8, IL-1β)

Interleukin-6, Interleukin-8, and Interleukin-1 beta (IL-1β) cytokine expression refers to the production and secretion of three pivotal pro-inflammatory signaling proteins that drive systemic immune responses. Interleukin-6 (IL-6) is a pleiotropic cytokine that regulates the acute-phase response and B-cell maturation (UniProt:P05231), while Interleukin-8 (IL-8/CXCL8) is a primary chemokine responsible for neutrophil recruitment to sites of inflammation (UniProt:P10145). Interleukin-1 beta (IL-1β) is a potent mediator of the inflammatory response, often activated by the NLRP3 inflammasome, that induces fever and activates vascular endothelium (UniProt:P01584). The simultaneous elevation of these cytokines is a hallmark of "cytokine storms" and hyperinflammatory states associated with sepsis, COVID-19, and cytokine release syndrome (PMID: 33264547). While "cytokine expression" itself is a biological process rather than a single therapeutic target, the individual components are major targets for drug development. Therapeutic interventions include monoclonal antibodies that neutralize the cytokines or block their receptors (e.g., tocilizumab for IL-6R or canakinumab for IL-1β) to dampen the inflammatory cascade (DrugBank:DB06273, DB00026). Monitoring the expression levels of these cytokines serves as a critical biomarker for disease severity and therapeutic efficacy in clinical settings.

Other names

Inflammatory cytokine panelPro-inflammatory cytokine profileCytokine storm markersIL6/IL8/IL1B expression

Therapeutic agents target this cytokine profile by either directly neutralizing the cytokines (e.g., canakinumab for IL-1β, siltuximab for IL-6), blocking their cognate receptors (e.g., tocilizumab for IL-6R, anakinra for IL-1R), or inhibiting upstream signaling pathways such as the JAK/STAT or NF-κB pathways to reduce their overall expression and secretion.